Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Smartleaf Asset Management LLC grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 29.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 871 shares of the biopharmaceutical company’s stock after acquiring an additional 197 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Halozyme Therapeutics were worth $42,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 173.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,028 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Halozyme Therapeutics by 38.4% in the third quarter. Janney Montgomery Scott LLC now owns 36,020 shares of the biopharmaceutical company’s stock valued at $2,062,000 after acquiring an additional 9,995 shares in the last quarter. QRG Capital Management Inc. purchased a new stake in shares of Halozyme Therapeutics during the third quarter worth $245,000. Assetmark Inc. lifted its stake in Halozyme Therapeutics by 9.9% in the 3rd quarter. Assetmark Inc. now owns 93,159 shares of the biopharmaceutical company’s stock worth $5,332,000 after purchasing an additional 8,385 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its stake in shares of Halozyme Therapeutics by 6.3% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 13,734 shares of the biopharmaceutical company’s stock worth $786,000 after acquiring an additional 815 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,697 shares of company stock worth $1,754,451. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $61.45 on Wednesday. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $65.53. The company has a market capitalization of $7.57 billion, a P/E ratio of 17.92, a PEG ratio of 0.42 and a beta of 1.32. The business has a 50 day moving average price of $55.96 and a 200 day moving average price of $54.68. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on HALO shares. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Piper Sandler increased their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Benchmark reissued a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.